Foundation Fighting Blindness

Foundation Fighting Blindness
  • 0,0 (0)
  • Ciencias

The Foundation Fighting Blindness is the driving force in the global development of treatments and cures for blinding diseases. To learn more, go to FightingBlindness.org.

  1. hace 1 d

    Tarsus plans to purchase Alkeus, developer of emerging Stargardt treatment

    Tarsus Pharmaceuticals announced plans to acquire Alkeus Pharmaceuticals, including its emerging oral treatment for Stargardt disease, gildeuretinol (ALK-001), in a deal valued up to $800 million. Stargardt disease is the most common form of inherited macular degeneration and is often diagnosed in children or teens. There are no current treatments.

    Tarsus plans to purchase Alkeus, developer of emerging Stargardt treatment

  2. hace 6 d

    PRIMA retinal implant restores sight in patients with geographic atrophy from AMD

    In Europe, Science Corporation has commercially launched PRIMA, a retinal implant designed to restore central vision in people with geographic atrophy (GA). The treatment has been shown in clinical trials to restore functional central vision in people with GA who until now had no way to get lost central vision back. While PRIMA is available in Europe, it is still going through FDA approvals in the U.S. Geographic atrophy is an advanced form of age-related macular degeneration (AMD) that leads to progressive vision loss. AMD is the most common cause of blindness in individuals over the age of 55 in developed countries.

    PRIMA retinal implant restores sight in patients with geographic atrophy from AMD

  3. 14 ago

    FDA accepts new drug application, prioritizes review for potential Stargardt treatment

    Belite Bio’s tinlarebant could become the first-ever approved treatment for Stargardt disease

    FDA accepts new drug application, prioritizes review for potential Stargardt treatment

  4. 5 ago

    Eye on the Cure Podcast | Episode 102: What is Venture Philanthropy?

    Dr. Alicia Kemble explains how the Foundation is using venture philanthropy to drive treatments for inherited retinal diseases even closer to the finish line.

    Eye on the Cure Podcast | Episode 102: What is Venture Philanthropy?

  5. 24 jul

    Sepul Bio completes clinical trial enrollment for its USH2A retinitis pigmentosa treatment

    Sepul Bio recently announced that it completed enrollment of its Phase 2b safety and efficacy clinical trial for ultevursen – an investigational RNA therapy to treat patients who have retinitis pigmentosa (RP) associated with mutations in the USH2A gene.

    Sepul Bio completes clinical trial enrollment for its USH2A retinitis pigmentosa treatment

  6. 16 jul

    FDA approves Lumvoa, a new treatment for thyroid eye disease

    FDA approves Lumvoa, a new treatment for thyroid eye disease by Foundation Fighting Blindness

    FDA approves Lumvoa, a new treatment for thyroid eye disease

  7. 6 jul

    Belite Bio submits new drug application to FDA for its Stargardt treatment

    Belite Bio submits new drug application to FDA for its Stargardt treatment by Foundation Fighting Blindness

    Belite Bio submits new drug application to FDA for its Stargardt treatment

  8. 1 jul

    Eye on the Cure Podcast | Episode 101: Dr. Patrick Staropoli

    New host Maddie Mossman interviews retinal surgeon Dr. Staropoli, the first medical doctor to win a NASCAR race.

    Eye on the Cure Podcast | Episode 101: Dr. Patrick Staropoli
Ver todo (267)

Información

The Foundation Fighting Blindness is the driving force in the global development of treatments and cures for blinding diseases. To learn more, go to FightingBlindness.org.

Ficha técnica

  • Creado por
    Foundation Fighting Blindness
  • Años en activo
    2021 - 2026
  • Episodios
    267
  • Clasificación
    Apto
  • Derechos de autor
    © All rights reserved
  • Sitio web del podcast
    Foundation Fighting Blindness

Quizá también te guste